Global Vebreltinib Enteric Capsules 麻豆原创 Research Report 2025

Publication ID:

PB506256459

Publication Date:

June 16, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Vebreltinib Enteric Capsules was valued at US$ 41.0 million in the year 2024 and is projected to reach a revised size of US$ 139 million by 2031, growing at a CAGR of 19.0% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Vebreltinib Enteric Capsules competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Vebreltinib enteric capsules are an oral medication used in the treatment of cancers with specific MET gene alterations, particularly in cases of non-small cell lung cancer (NSCLC). Vebreltinib is a selective MET receptor tyrosine kinase inhibitor that targets and blocks the MET receptor, which is involved in tumor growth and metastasis.
Vebreltinib (brand name: Wanbirui庐) is a highly selective c-Met inhibitor developed by Crown Bioscience Taicang, a subsidiary of Crown Bioscience Inc. On November 16, 2023, vebreltinib received conditional approval from the China National Medical Products Administration (NMPA) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. This approval marks a significant milestone for domestically developed precision oncology therapies targeting MET alterations.
At the 2023 ESMO Congress, results from the pivotal Phase II KUNPENG trial were presented, showing impressive efficacy in METex14-altered advanced NSCLC. The objective response rate (ORR) was 75.0%, with a median progression-free survival (mPFS) of 14.1 months and median overall survival (OS) of 20.7 months. These results position vebreltinib competitively against global MET inhibitors. The treatment demonstrated a favorable safety profile, with the most common treatment-related adverse events being peripheral edema (56.6%), hypoalbuminemia (22.1%), and hypoproteinemia (19.5%), mostly Grade 1 or 2 in severity. No significant irreversible or fatal toxicities were reported.
The enteric capsule formulation is designed to protect the active compound from degradation in the acidic stomach environment, thereby improving oral bioavailability and reducing gastric irritation. This formulation offers advantages in patient compliance and pharmacokinetic consistency, making it well-suited for long-term cancer therapy.
In the market landscape, vebreltinib competes with existing MET inhibitors such as Capmatinib (Novartis) and Tepotinib (Takeda), both of which are imported and priced at a premium. As a domestically developed product, vebreltinib is well-positioned for broader accessibility through national reimbursement negotiations and aligns with China's strategic goal of achieving self-sufficiency in high-end therapeutics. With the growing adoption of next-generation sequencing (NGS), MET mutations are increasingly identified, expanding the eligible patient population. Vebreltinib is also under investigation for additional indications including MET amplification, RET fusions, and gliomas, suggesting potential as a pan-cancer targeted therapy. Its strong clinical efficacy, manageable safety profile, optimized formulation, and domestic origin collectively indicate that vebreltinib is poised to secure a significant share in China's MET-targeted therapy market and potentially in global oncology as well.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Vebreltinib Enteric Capsules, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vebreltinib Enteric Capsules.
The Vebreltinib Enteric Capsules market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Vebreltinib Enteric Capsules market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vebreltinib Enteric Capsules manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Avistone Pharmaceuticals Biotechnology
Asymchem
Segment by Type
25mg per Unit
100mg per Unit
Segment by Application
Glioma
Non-small Cell Lung Cancer
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Vebreltinib Enteric Capsules manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Vebreltinib Enteric Capsules in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Vebreltinib Enteric Capsules 麻豆原创 Overview
1.1 Product Definition
1.2 Vebreltinib Enteric Capsules by Type
1.2.1 Global Vebreltinib Enteric Capsules 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 25mg per Unit
1.2.3 100mg per Unit
1.3 Vebreltinib Enteric Capsules by Application
1.3.1 Global Vebreltinib Enteric Capsules 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Glioma
1.3.3 Non-small Cell Lung Cancer
1.4 Global Vebreltinib Enteric Capsules 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Vebreltinib Enteric Capsules Revenue 2020-2031
1.4.2 Global Vebreltinib Enteric Capsules Sales 2020-2031
1.4.3 Global Vebreltinib Enteric Capsules 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Vebreltinib Enteric Capsules 麻豆原创 Competition by Manufacturers
2.1 Global Vebreltinib Enteric Capsules Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Vebreltinib Enteric Capsules Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Vebreltinib Enteric Capsules Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Vebreltinib Enteric Capsules, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Vebreltinib Enteric Capsules, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Vebreltinib Enteric Capsules, Product Type & Application
2.7 Global Key Manufacturers of Vebreltinib Enteric Capsules, Date of Enter into This Industry
2.8 Global Vebreltinib Enteric Capsules 麻豆原创 Competitive Situation and Trends
2.8.1 Global Vebreltinib Enteric Capsules 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Vebreltinib Enteric Capsules Players 麻豆原创 Share by Revenue
2.8.3 Global Vebreltinib Enteric Capsules Company Type and 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Vebreltinib Enteric Capsules 麻豆原创 Scenario by Region
3.1 Global Vebreltinib Enteric Capsules 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Vebreltinib Enteric Capsules Sales by Region: 2020-2031
3.2.1 Global Vebreltinib Enteric Capsules Sales by Region: 2020-2025
3.2.2 Global Vebreltinib Enteric Capsules Sales by Region: 2026-2031
3.3 Global Vebreltinib Enteric Capsules Revenue by Region: 2020-2031
3.3.1 Global Vebreltinib Enteric Capsules Revenue by Region: 2020-2025
3.3.2 Global Vebreltinib Enteric Capsules Revenue by Region: 2026-2031
3.4 North America Vebreltinib Enteric Capsules 麻豆原创 Facts & Figures by Country
3.4.1 North America Vebreltinib Enteric Capsules 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Vebreltinib Enteric Capsules Sales by Country (2020-2031)
3.4.3 North America Vebreltinib Enteric Capsules Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Vebreltinib Enteric Capsules 麻豆原创 Facts & Figures by Country
3.5.1 Europe Vebreltinib Enteric Capsules 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Vebreltinib Enteric Capsules Sales by Country (2020-2031)
3.5.3 Europe Vebreltinib Enteric Capsules Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vebreltinib Enteric Capsules 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Vebreltinib Enteric Capsules 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Vebreltinib Enteric Capsules Sales by Region (2020-2031)
3.6.3 Asia Pacific Vebreltinib Enteric Capsules Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Vebreltinib Enteric Capsules 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Vebreltinib Enteric Capsules 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Vebreltinib Enteric Capsules Sales by Country (2020-2031)
3.7.3 Latin America Vebreltinib Enteric Capsules Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Vebreltinib Enteric Capsules 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Vebreltinib Enteric Capsules 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Vebreltinib Enteric Capsules Sales by Country (2020-2031)
3.8.3 Middle East and Africa Vebreltinib Enteric Capsules Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Vebreltinib Enteric Capsules Sales by Type (2020-2031)
4.1.1 Global Vebreltinib Enteric Capsules Sales by Type (2020-2025)
4.1.2 Global Vebreltinib Enteric Capsules Sales by Type (2026-2031)
4.1.3 Global Vebreltinib Enteric Capsules Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Vebreltinib Enteric Capsules Revenue by Type (2020-2031)
4.2.1 Global Vebreltinib Enteric Capsules Revenue by Type (2020-2025)
4.2.2 Global Vebreltinib Enteric Capsules Revenue by Type (2026-2031)
4.2.3 Global Vebreltinib Enteric Capsules Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Vebreltinib Enteric Capsules Price by Type (2020-2031)
5 Segment by Application
5.1 Global Vebreltinib Enteric Capsules Sales by Application (2020-2031)
5.1.1 Global Vebreltinib Enteric Capsules Sales by Application (2020-2025)
5.1.2 Global Vebreltinib Enteric Capsules Sales by Application (2026-2031)
5.1.3 Global Vebreltinib Enteric Capsules Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Vebreltinib Enteric Capsules Revenue by Application (2020-2031)
5.2.1 Global Vebreltinib Enteric Capsules Revenue by Application (2020-2025)
5.2.2 Global Vebreltinib Enteric Capsules Revenue by Application (2026-2031)
5.2.3 Global Vebreltinib Enteric Capsules Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Vebreltinib Enteric Capsules Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Avistone Pharmaceuticals Biotechnology
6.1.1 Avistone Pharmaceuticals Biotechnology Company Information
6.1.2 Avistone Pharmaceuticals Biotechnology Description and Business Overview
6.1.3 Avistone Pharmaceuticals Biotechnology Vebreltinib Enteric Capsules Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Avistone Pharmaceuticals Biotechnology Vebreltinib Enteric Capsules Product Portfolio
6.1.5 Avistone Pharmaceuticals Biotechnology Recent Developments/Updates
6.2 Asymchem
6.2.1 Asymchem Company Information
6.2.2 Asymchem Description and Business Overview
6.2.3 Asymchem Vebreltinib Enteric Capsules Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Asymchem Vebreltinib Enteric Capsules Product Portfolio
6.2.5 Asymchem Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vebreltinib Enteric Capsules Industry Chain Analysis
7.2 Vebreltinib Enteric Capsules Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vebreltinib Enteric Capsules Production Mode & Process Analysis
7.4 Vebreltinib Enteric Capsules Sales and 麻豆原创ing
7.4.1 Vebreltinib Enteric Capsules Sales Channels
7.4.2 Vebreltinib Enteric Capsules Distributors
7.5 Vebreltinib Enteric Capsules Customer Analysis
8 Vebreltinib Enteric Capsules 麻豆原创 Dynamics
8.1 Vebreltinib Enteric Capsules Industry Trends
8.2 Vebreltinib Enteric Capsules 麻豆原创 Drivers
8.3 Vebreltinib Enteric Capsules 麻豆原创 Challenges
8.4 Vebreltinib Enteric Capsules 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Avistone Pharmaceuticals Biotechnology
Asymchem

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.